Edwards Lifesciences Corporation
EW
$81.83
$0.670.83%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.89% | 6.23% | 9.43% | 8.93% | 8.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.89% | 6.23% | 9.43% | 8.93% | 8.47% |
| Cost of Revenue | 25.01% | 5.12% | 16.41% | 4.91% | 15.85% |
| Gross Profit | 8.58% | 6.53% | 7.70% | 9.94% | 6.75% |
| SG&A Expenses | 12.18% | 8.71% | 18.27% | 10.34% | 11.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 87.10% | -- | -- |
| Total Operating Expenses | 10.71% | 3.17% | 40.87% | 9.69% | -2.66% |
| Operating Income | 15.03% | 14.53% | -33.71% | 7.12% | 55.76% |
| Income Before Tax | 4.22% | 16.89% | 6.24% | 3.92% | 42.17% |
| Income Tax Expenses | 221.50% | 51.84% | 32.26% | -22.77% | -1.48% |
| Earnings from Continuing Operations | -7.72% | 11.91% | 3.57% | 8.12% | 45.72% |
| Earnings from Discontinued Operations | -540.00% | -127.59% | 7.38% | 5,447.75% | -98.20% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 30.77% | 77.78% | 550.00% | 16.67% | -18.75% |
| Net Income | -9.04% | 1.73% | 4.24% | 697.82% | 19.28% |
| EBIT | 15.03% | 14.53% | -33.71% | 7.12% | 55.76% |
| EBITDA | 13.23% | 12.64% | -30.51% | 5.88% | 49.75% |
| EPS Basic | -6.71% | 4.29% | 6.97% | 710.91% | 20.24% |
| Normalized Basic EPS | 16.99% | 15.99% | -29.27% | 15.87% | 54.09% |
| EPS Diluted | -7.54% | 4.22% | 7.08% | 716.06% | 20.24% |
| Normalized Diluted EPS | 17.25% | 16.31% | -29.16% | 16.18% | 54.40% |
| Average Basic Shares Outstanding | -2.51% | -2.44% | -2.54% | -1.61% | -0.79% |
| Average Diluted Shares Outstanding | -2.71% | -2.70% | -2.70% | -1.87% | -0.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |